Small molecule drugs for the treatment of rheumatoid arthritis
DOI:
https://doi.org/10.54097/0m41x597Keywords:
Rheumatoid arthritis, small molecule drugs, Signaling pathways.Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints but can also involve other parts of the body. In 2019, an estimated 18 million people across the globe were living with rheumatoid arthritis (RA). Among these individuals, approximately 13 million experienced varying degrees of severity in their RA symptoms. Rheumatoid arthritis (RA) is a multifaceted systemic autoimmune disorder affected by both genetic predisposition and environmental factors, leading to inflammation in the synovial tissue and dysregulation of the immune system. This dysregulation is driven by abnormal cytokines and immune cells, which significantly contribute to the pathogenesis and advancement of the disease. Presently, treatments for RA mainly concentrate on relieving symptoms and achieving disease remission through the use of disease-modifying antirheumatic drugs (DMARDs). These DMARDs encompass conventional DMARDs (cDMARDs) like methotrexate and targeted DMARDs such as JAK inhibitors. Biologic DMARDs (bDMARDs) have also been used but have many limitations. This review explored the different signaling pathways crucial for RA development, as well as the small-molecule drugs that specifically target these pathways.
Downloads
References
Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6 (1): 1 – 4.
Yap H-Y, Tee S, Wong M, Chow S-K, Peh S-C, Teow S-Y (2018) Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells 7 (10): 161.
Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z (2013) Genetics of rheumatoid arthritis—a comprehensive review. Clin Rev Allergy Immunol 45 (2): 170 – 179.
Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol. 2016 Jun; 32: 29 - 33.
Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA. Division Director Summary Review.
LaBranche, T. P., Jesson, M.I., Radi, Z.A., Storer, C. E., Guzova, J.A., Bonar, S. L., Thompson, J.M., Happa, F. A., Stewart, Z.S., Zhan, Y., Bollinger, C.S., Bansal, P. N., Wellen, J.W., Wilkie, D.P., Bailey, S. A., Symanowicz, P.T., Hegen, M., Head, R.D., Kishore, N., Mbalaviele, G. and Meyer, D. M. (2012), JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis & Rheumatism, 64: 3531 - 3542.
Raj Nair, MD Clinical Reviewer Division of Pulmonary, Allergy, and Rheumatology Products (DPARP) Nikolay P. Nikolov, MD Supervisory Associate Director, Rheumatology, DPARP Sally Seymour, MD Acting Division Director, DPARP Mary T. Thanh Hai, MD Acting Director Office of Drug Evaluation II Office of New Drugs Center for Drug Evaluation and Research, Summary review.
Mark C. Genovese, M.D., Joel Kremer, M.D., Omid Zamani, M.D., Charles Ludivico, M.D., Marek Krogulec, M.D., Li Xie, M.S., Scott D. Beattie, Ph.D., Alisa E. Koch, M.D., Tracy E. Cardillo, M.S., Terence P. Rooney, Baricitinib in Patients with Refractory Rheumatoid Arthritis, N Engl J Med 2016; 374: 1243 - 1252.
Rachel Glaser, MD, Clinical Team Leader, DPARP Sally Seymour, MD, Director, DP ARP Marv Thanh Hai, MD, Acting Director, ODEII. Summary review.
Fertig BA, Baillie GS. PDE4-Mediated cAMP Signalling. J Cardiovasc Dev Dis. 2018 Jan 31; 5 (1): 8.
Jin J, Mazzacuva F, Crocetti L, Giovannoni MP, Cilibrizzi A. PDE4 Inhibitors: Profiling Hits through the Multitude of Structural Classes. Int J Mol Sci. 2023 Jul 15; 24 (14): 11518.
Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Division Director Summary Review.
Keating GM. Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs. 2017 Mar; 77 (4): 459 - 472.
Palma M, Mulder TA, Österborg A. BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects. Front Immunol. 2021 Jul 1; 12: 686768.
Arneson LC, Carroll KJ, Ruderman EM. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis. Immunotargets Ther. 2021 Aug 28; 10: 333 - 342.
Schafer PH, Kivitz AJ, Ma J, Korish S, Sutherland D, Li L, Azaryan A, Kosek J, Adams M, Capone L, Hur EM, Hough DR, Ringheim GE. Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study. Rheumatol Ther. 2020 Mar; 7 (1): 101 - 119.
Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A, Pawlak D. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. Molecules. 2023 Mar 6; 28 (5): 2400.
Cohen S, Tuckwell K, Katsumoto TR, Zhao R, Galanter J, Lee C, Rae J, Toth B, Ramamoorthi N, Hackney JA, Berman A, Damjanov N, Fedkov D, Jeka S, Chinn LW, Townsend MJ, Morimoto AM, Genovese MC. Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study). Arthritis Rheumatol. 2020 Apr 9; 72 (9): 1435 – 46.
Study to evaluate safety and pharmacokinetics of GS-4059 (tirabrutinib) in healthy volunteers and participants with Rheumatoid Arthritis (RA). Available from: https: //ClinicalTrials.gov/show/NCT02626026. Accessed August4, 2021.
Safety and Efficacy Study of M2951 in participants with rheumatoid arthritis. Available from: https: //ClinicalTrials.gov/show/NCT02784106. Accessed August4, 2021.
Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A, Bachmann A, Dong J, van Lier JJ, Tracewell W, Mitchell D. Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. Clin Transl Sci. 2021 Nov; 14 (6): 2420 - 2430.
Ringheim GE, Wampole M, Oberoi K. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Front Immunol. 2021 Nov 3; 12: 662223.
Pamuk, O.N., Tsokos, G.C. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 12, 222 (2010).
Tümmler C, Dumitriu G, Wickström M, Coopman P, Valkov A, Kogner P, Johnsen JI, Moens U, Sveinbjörnsson B. SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro. Cancers (Basel). 2019 Feb 10; 11 (2): 202.
Matsukane R, Suetsugu K, Hirota T, Ieiri I. Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406. Clin Pharmacokinet. 2022 Jul; 61 (7): 955 - 972.
Sirico M, D'Angelo A, Gianni C, Casadei C, Merloni F, De Giorgi U. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers (Basel). 2023 Jan 23; 15 (3): 703.
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. Cell. 2017 Aug 10; 170 (4): 605 - 635.
Junjie Yang, Jiayu Liu, Jing Li, Ming Jing, Leiming Zhang, Mengmeng Sun, Qiaoyun Wang, Hongliu Sun, Guige Hou, Chunhua Wang, Wenyu Xin,Celastrol inhibits rheumatoid arthritis by inducing autophagy via inhibition of the PI3K/AKT/mTOR signaling pathway, International Immunopharmacology, Volume 112, 2022, 109241, ISSN 1567 - 5769,
Camps, M., Rückle, T., Ji, H. et al. Blockade of PI3Kγ suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11, 936 – 943 (2005).
Kim J, Jung KH, Yoo J, Park JH, Yan HH, Fang Z, Lim JH, Kwon SR, Kim MK, Park HJ, Hong SS. PBT-6, a Novel PI3KC2γ Inhibitor in Rheumatoid Arthritis. Biomol Ther (Seoul). 2020 Mar 1; 28 (2): 172 - 183.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
